Naturecell KRX:007390KOSDAQ
네이처셀 · Korean news coverage and regulatory filings, organized.
Articles, 24h1
Articles, 7 days1
DART filings, 7 days0
Articles tracked1since Sep 11
In Q2 2026, Naturecell reported revenue of ₩6.2bn, down 3.3% year on year, and an operating loss of ₩702m. Naturecell (네이처셀) appeared in 1 Korean news article and 0 DART filings over the past seven days. Coverage peaked on Sep 15 with 1 article. The most common catalyst was clinical & approvals (1).
Filing signals 4 quarters of losses Screener
Naturecell quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩6.2bn | -3.3% | −₩702m | −₩637m |
| Q1 2026 | ₩4.1bn | -0.4% | −₩1.3bn | −₩1.1bn |
| Q4 2025 derived | ₩6.4bn | -17.9% | −₩261m | ₩340m |
| Q3 2025 | ₩3.9bn | -33.0% | −₩1.4bn | −₩1.3bn |
| Q2 2025 | ₩6.4bn | -33.5% | −₩287m | −₩668m |
| Q1 2025 | ₩4.1bn | -55.1% | −₩1.7bn | −₩1.2bn |
| Q4 2024 derived | ₩7.7bn | +93.2% | ₩196m | ₩311m |
| Q3 2024 | ₩5.8bn | +50.8% | −₩986m | −₩539m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Naturecell top stories 2 weeks, by number of outlets
- 1